In the News

Share
1731 News Items found
Rob with his wife and daughter
FDA Approves Zanidatamab for Biliary Tract Cancers With High HER2 Levels 
Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved by the FDA, thanks to a clinical trial co-led by MSK.
A researcher working in an MSK lab
MSK Research Highlights, November 21, 2024
New MSK research investigates how pancreatic cancer cells regulate their genome to avoid immune attack; shows promise against glioblastoma in mouse models; and develops a new method to study cancer evolution.
Sohrab Shah
Cancer-Like Mutations in Healthy Cells Point to Origins of Breast Cancer
A multi-institution team co-led by MSK researchers has pinpointed what could be the early genetic origins of breast cancer.
Michael Rosensweig with dog
FDA Approves Revumenib, a Menin Inhibitor, for Aggressive Leukemia
Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients one year and older who have leukemia that has come back after treatment and whose cancer carries a molecular change called a KMT2A translocation.
Q&A
Hematologic oncologist Eytan Stein and nurse practitioner Coleen Ranaghan consult with a patient.
How Acute Myeloid Leukemia Is Treated at MSK: An Interview With Eytan Stein
In this interview, hematologic oncologist Eytan Stein, Director of the Program for Drug Development in Leukemia, talks about the latest advances in treatment for AML and how people can benefit from receiving their treatment at MSK.
Ask the Expert
Thoracic medical oncologist Dr. Mark Awad
New Lung Cancer Treatments Aim to Reduce Deaths in 2025 and Beyond
Learn about the latest advances in lung cancer treatment at MSK.
Dr. Michael Tuttle consults with a patient in an exam room
Why Active Surveillance Is a Good Option for Many Patients With Papillary Thyroid Cancer
Learn about MSK’s active surveillance program for papillary thyroid cancer, which allows many people to avoid unnecessary surgery and the risks that come with it.
a lab coat hangs in an MSK lab
MSK Research Highlights, November 6, 2024
New MSK research marks a potential advance against RAS-driven cancers; breaks down data silos to better predict cancer outcomes with the help of artificial intelligence (AI); identifies two enzymes vital for maintaining brain health; uncovers how changes to “helper” proteins drive cancer cell survival; develops a new model for investigating lung cancer metastasis; and uses AI to improve outcome predictions in sarcoma.
Dr. Craig Thompson in his lab at the Sloan Kettering Institute
New MSK Research Reveals How Mitochondria Function Under Stress Like Cancer
Mitochondria provide both the energy cells need to survive and the building blocks they need to grow and divide. Researchers at the Sloan Kettering Institute reveal for the first time how mitochondria choose between these opposing paths — and what implications it may have for cancer.
John Petrini
Ancient Immune Defense System Plays an Unexpected Role in Cancer, MSK Researchers Find
Along with defending against pathogens, the body’s innate immune system helps to protect the stability of our genomes in unexpected ways — ways that have important implications for the development of cancer, researchers at MSK are discovering.